Skip to main content
SpringerLink
Log in

Internal Radiotherapy Using Radionuclides

  • Chapter
  • First Online:
Radiotherapy of Liver Cancer

  • 594 Accesses

Abstract

Selective internal radiation therapy (SIRT) is a form of locoregional treatment using radiation from radiolabelled particles or ligands for liver cancer. This modality has seen significant advancements in recent times with robust scientific evidence backing the expanding therapeutic applications. The common indications for SIRT are reviewed based on current evidence, including the results of major clinical trials. Technological advances in hybrid imaging and interventional radiology have contributed to the use of planning dosimetry for dose activity prescriptions. There is emerging data to show that this leads to better patient outcomes. The recent phase III trials have also highlighted a good safety profile and better tolerance of SIRT compared to the current standard of care systemic treatment. There is potential for combining external beam radiotherapy with SIRT under certain clinical circumstances and new data will be eagerly expected in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ariel IM. Radioactive isotopes for adjuvant cancer therapy; animal experimentation and preliminary results in human application. Arch Surg. 1964;89:244–9.

    Article  CAS  Google Scholar 

  2. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting CW, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.

    Article  Google Scholar 

  3. Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med. 2019;49(3):237–43.

    Article  Google Scholar 

  4. Braat AJAT, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561–70.

    Article  CAS  Google Scholar 

  5. Gray BN. Colorectal cancer: the natural history of disseminated disease—a review. Aust N Z J Surg. 1980;50:643–6.

    Article  CAS  Google Scholar 

  6. Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943.

    Article  Google Scholar 

  7. Teo JY, Allen JC Jr, Ng DC, et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford). 2016;18(1):7–12.

    Article  Google Scholar 

  8. Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013;24(11):1632–8.

    Article  Google Scholar 

  9. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7.

    Article  CAS  Google Scholar 

  10. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868–78.

    Article  Google Scholar 

  11. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–63.

    Article  Google Scholar 

  12. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–8.

    Article  CAS  Google Scholar 

  13. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocculalar carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

    Article  CAS  Google Scholar 

  14. Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.

    Article  CAS  Google Scholar 

  15. Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018;7(6):487–9.

    Article  Google Scholar 

  16. Ricke J, Klumpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164–74.

    Article  CAS  Google Scholar 

  17. Venerito M, Pech M, Canbay A, et al. NEMESIS: non-inferiority, individual patient meta-analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61(12):1736–42. https://doi.org/10.2967/jnumed.120.242933.

    Article  CAS  PubMed  Google Scholar 

  18. Garin E, Tzelikas L, Guiu B, et al. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: final overall survival analysis of a multicentre randomized phase II study (DOSISPHERE-01). J Clin Oncol. 2020;38(4_suppl):516.

    Article  Google Scholar 

  19. Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53:559–66.

    Article  CAS  Google Scholar 

  20. Rodriguez LS, Thang SP, Li H, et al. A descriptive analysis of remnant activity during (90)Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications. Ann Nucl Med. 2016;30(3):255–61.

    Article  Google Scholar 

  21. Gnesin S, Canetti L, Adib S, et al. Partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with 90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–8.

    Article  CAS  Google Scholar 

  22. Ho CL, Chen S, Cheung SK, et al. Radioembolization with Y-90 glass microspheres for hepatocellular carcinoma: significance of pretreatment C-11 acetate and FDG PET/CT and posttreatment Y-90 PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110–21.

    Article  CAS  Google Scholar 

  23. Garin E, Lenoir L, Rolland Y, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.

    Article  CAS  Google Scholar 

  24. Garin E, Rolland Y, Edeline J. 90Y-loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of 99mTc-MAA SPECT/CT-based dosimetry. Semin Nucl Med. 2019;49(3):218–26.

    Article  Google Scholar 

  25. Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.

    Article  CAS  Google Scholar 

  26. Levillain H, Duran Derijckere I, Ameye L, et al. Personalizsed radioembolization improves outcomes in refractory intrahepatic cholangiocarcinoma: a multicentre study. Eur J Nucl Med Mol Imag. 2019;46(11):2270–9.

    Article  Google Scholar 

  27. Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401–7.

    Article  Google Scholar 

  28. Lam MG, Goris ML, Iagaru AH, et al. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. J Nucl Med. 2013;54(12):2055–61.

    Article  CAS  Google Scholar 

  29. Lam MG, Louie JD, Iagaru AH, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1320–8.

    Article  Google Scholar 

  30. Zarva A, Mohnike K, Damm R, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55:360–6.

    Article  Google Scholar 

  31. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163–71.

    Article  Google Scholar 

  32. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicentre radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201.

    Article  Google Scholar 

  33. Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, et al. Post-radioembolization yttrium-90 PET/CT—part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res. 2013;3:57.

    Article  Google Scholar 

  34. Leung TW, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33(4):919–24.

    Article  CAS  Google Scholar 

  35. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078–87.

    Article  CAS  Google Scholar 

  36. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of Lu-177 Dotatate for midgut neuroendocrine tumours. N Engl J Med. 2017;376:125–35.

    Article  CAS  Google Scholar 

  37. Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18(5):595–602.

    Article  CAS  Google Scholar 

  38. Murthy R, Kamat P, Nuñez R, Salem R. Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Intervent Radiol. 2008;25(1):48–57.

    Article  Google Scholar 

  39. Lam MG, Abdelmaksoud MH, Chang DT, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323–9.

    Article  Google Scholar 

  40. Wang TH, Huang PI, Hu YW, et al. Combined yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: from clinical aspects to dosimetry. PLoS One. 2018;13(1):e0190098.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore

    Aaron Kian-Ti Tong & David Chee-Eng Ng

  2. Radiological Sciences Academic Clinical Programme, DUKE-NUS Medical School, Singapore, Singapore

    Aaron Kian-Ti Tong & David Chee-Eng Ng

  3. Surgery and Surgical Oncology, Singapore General Hospital and National Cancer Center Singapore, Singapore, Singapore

    Pierce Kah-Hoe Chow

  4. Surgery Academic Clinical Programme, DUKE-NUS Medical School, Singapore, Singapore

    Pierce Kah-Hoe Chow

Authors
  1. Aaron Kian-Ti Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Chee-Eng Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierce Kah-Hoe Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron Kian-Ti Tong .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea (Republic of)

    Jinsil Seong

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tong, A.KT., Ng, D.CE., Chow, P.KH. (2021). Internal Radiotherapy Using Radionuclides. In: Seong, J. (eds) Radiotherapy of Liver Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-16-1815-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-1815-4_10

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-1814-7

  • Online ISBN: 978-981-16-1815-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation